FTC targets middlemen in generic drug shortages probe
pharmaphorum
FEBRUARY 15, 2024
The FTC is investigating wholesalers and other middlemen in the pharma supply chain to assess their possible role in worsening shortages of generic medicines
Generic Medicine Related Topics 
Opinion: I went on a mind-boggling journey to get my son’s ADHD medication covered by insurance — twice
STAT
JANUARY 5, 2024
As a former editor for diabetes publications, I knew that insurance companies regularly switched people from one brand of insulin to another, or from a name brand of insulin to a generic. However, I had used generic medicine for my blood pressure without a problem, so I hoped for the best with this switch.
Insurance 
118
118 Join 18,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
STAT+: Many costly generic drugs are unavailable at Amazon, Cuban, and other alternative pharmacies
STAT
MARCH 1, 2024
A growing number of alternative pharmacies — such as those run by Costco, Amazon, and Mark Cuban Cost Plus Drugs — may be increasingly popular with American consumers, but a new analysis finds many of the most expensive generic medicines are unavailable, prices vary widely, and savings can be modest.
Generic Medicine 120
120 Generic Medicine 120
120 
NHS drug shortages are partly a political failure | Letters
The Guardian - Pharmaceutical Industry
JANUARY 22, 2024
Roared on by the pharmaceutical industry, ministers have been using trade talks with India to push for agreement on new, extremely restrictive patent rules that would severely undermine its generic medicines industry.
STAT+: Generic makers fall short when providing access to low- and middle-income countries, analysis finds
STAT
SEPTEMBER 29, 2023
A handful of the largest purveyors of generic medicines have made only halting progress to ensure their drugs are accessible for patients in low- and middle-income countries, a new analysis found.
Generic Medicine 109
109 Generic Medicine 109
109 
India's Torrent scouts for funding to make a play for larger rival Cipla: Reuters
Fierce Pharma
SEPTEMBER 19, 2023
Two large Indian suppliers of generic medicines in the U.S. and beyond are at the center of the industry's M&A rumor mill this week. Torrent is looking for financial help to potentially make a bid for its larger rival Cipla, according to Reuters.
STAT+: Congress highlighted a chemo drug’s price to blast PBMs — but it’s not a PBM issue
STAT
MAY 23, 2023
But it’s a generic medicine — which means PBMs’ negotiating techniques don’t apply. Generic drugs compete on price. There’s just one problem: PBMs don’t have anything to do with that discrepancy. The chemo drug in question, Imatinib, costs $17,000 at CVS and just $72 at Cost Plus Drugs.
STAT+: FTC challenges several big drugmakers over inaccurate or improper patent listings
STAT
NOVEMBER 7, 2023
The move comes two months after the FTC issued a policy statement noting some drug companies have failed to follow requirements for listing patents in the Food and Drug Administration’s Orange Book in hopes of thwarting competition from lower-cost generic medicines. Continue to STAT+ to read the full story…
Generic Medicine 118
118 Generic Medicine 118
118 
STAT+: Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal
STAT
MARCH 21, 2023
A leaked version of the agreement already sparked concerns last year that the proposed deal would impede the supply of affordable generic medicines in poor countries around the world. More than 200 civil society and patient advocacy groups are urging the U.K. Now, the groups are upset that the involvement of Harjinder Kang, the U.K.
Generic Medicine 100
100 
STAT+: FTC warns drugmakers they can face legal action over improper patent listings
STAT
SEPTEMBER 14, 2023
In explaining its new policy statement , the FTC noted that some drug companies have failed to follow requirements for listing patents in the so-called Orange Book in hopes of thwarting competition from lower-cost generic medicines.
Generic Medicine 123
123 
STAT+: A leaked version of a U.K.-India free trade deal sparks alarm over access to medicines
STAT
NOVEMBER 3, 2022
A leaked draft version of a trade agreement being negotiated between the United Kingdom and India has sparked concern among civil society and patient advocacy groups that the proposed deal would impede the supply of affordable generic medicines in poor countries around the world.
Generic Medicine 100
100 Generic Medicine 100
100 
The Guardian view on India-UK trade talks: don’t make it harder for the health service | Editorial
The Guardian - Pharmaceutical Industry
FEBRUARY 7, 2024
Britain is pushing for patent changes that could increase the cost of Indian generic drugs, diverting more of the NHS budget to big pharma India is known as the “ pharmacy of the world ”, supplying vital generic medicines at low prices to health services including the NHS.
STAT+: European regulator will review study data from contract research organization due to ‘serious concerns’
STAT
JULY 21, 2023
The review comes in response to an inspection of Synapse facilities by Spanish regulators, who raised “serious concerns about the validity and reliability” of clinical trial data generated by the company.
Indian doctors rebel over diktat to prescribe cheaper drugs
The Guardian - Pharmaceutical Industry
AUGUST 15, 2023
Indian Medical Association says that testing is substandard in the manufacture of generic medicines with ‘no guarantee of quality’ Indian doctors have been told they can no longer prescribe branded drugs for their patients, provoking vehement protest from the Indian Medical Association [IMA].
CHMP meeting highlights: January 2024
European Pharmaceutical Review
JANUARY 30, 2024
Ryzneuta (efbemalenograstim alfa) received a positive opinion from the CHMP as a medicine to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy. Additionally, a positive opinion for Niapelf (paliperidone), a generic medicine for schizophrenia was adopted in the meeting.
CHMP meeting highlights: February 2024
European Pharmaceutical Review
FEBRUARY 26, 2024
Other positive opinions by the CHMP Zynyz* (retifanlimab) as a treatment for Merkel cell carcinoma, a type of skin cancer Pyzchiva (ustekinumab), a biosimilar used to treat plaque psoriasis The generic medicine Apremilast Accord (apremilast), for psoriatic arthritis, psoriasis and Behçet’s disease, a rare type of inflammatory disease Generic medicine (..)
The critical role of the generics sector during the pandemic
pharmaphorum
DECEMBER 15, 2020
“Now more than ever, it is our responsibility as a sector to ensure affordable access to healthcare and enable the future longevity of medicine development and supply.”. The generics medicines sector can, too, play a substantial part in discovering new areas for licensed products to be used in. Delivery of essential medicines.
EMA human medicines committee (CHMP) highlights, September 2022
European Pharmaceutical Review
SEPTEMBER 21, 2022
Biosimilar medicine Ximluci (ranibizumab) for the treatment of neovascular age-related macular degeneration, a progressive retinal macular disease, causing gradual vision impairment, mainly in the elderly population.
KFA-115 by Novartis for Melanoma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
The company offers generic medicines and biosimilars through Sandoz. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others.
Parallel import of medicinal products: regulatory update
European Pharmaceutical Review
MARCH 14, 2023
The CJEU stressed that identical medicinal products are not those that are only therapeutically equivalent (as generics are to reference products), but they should be identical in all respects.
Packaging 83
83 
Rebranded Servier eyes €3bn in cancer drug sales by 2030
pharmaphorum
OCTOBER 6, 2022
” It also sees continued growth in cardiovascular and venous diseases, as well as in generic medicines, and says its new visual identity (see above) reflects its “uniqueness” as an “independent group, governed by a foundation, committed to therapeutic progress to serve patient needs.”
Novartis looking into future of its Sandoz’ generics business
pharmaphorum
OCTOBER 26, 2021
Novartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options – which would further narrow its focus to innovative medicines.
Generic Medicine 116
116 
Novartis announces plans to spin off Sandoz business
Pharmaceutical Technology
AUGUST 26, 2022
Last year, Sandoz generated sales worth $9.6bn and served more than 100 markets across the globe with a robust presence in the US, Europe and other regions. Upon becoming a standalone company, Sandoz would progress to make investments in the main strategic regions of antibiotics, biosimilars and generic medicines.
Sandoz bulks up ahead of possible sale with Coalesce buy
pharmaphorum
MARCH 14, 2022
For Sandoz, the acquisition gives it a technology platform in an area of the generic medicines market with a relatively high barrier to entry, as developing inhaled medicines poses “comparatively high technical complexity,” according to Sandoz chief executive Richard Saynor.
EMA human medicines committee (CHMP) highlights, November 2022
European Pharmaceutical Review
NOVEMBER 14, 2022
New generic medicine Pirfenidone Viatris (pirfenidone), received a positive opinion to treat idiopathic pulmonary fibrosis (IPF), a chronic and progressive condition where the lungs become scarred and breathing becomes increasingly difficult.
Vaccines 81
81 
US frets over pharma supply chain security
pharmaphorum
JUNE 22, 2022
The pharmaceutical industry is no different, with India and China becoming two of the leading manufacturers and exporters of generic medicine, as well as medical supplies, antibiotics and ingredients required to manufacture treatments.
Generic Medicine 106
106 
Astellas loses bid to block Lexiscan generics in US
pharmaphorum
JANUARY 4, 2023
It looks like Astellas has been unsuccessful in its attempt to block Pfizer’s generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexiscan in the US.
Sandoz to become standalone company
European Pharmaceutical Review
AUGUST 25, 2022
Meanwhile, Sandoz would leverage its strong brand and sustain its leading global position by continuing to invest in the key strategic areas of Biosimilars, Antibiotics and Generic Medicines. Working to deliver on its vision of access to patients. Additional transaction details.
KFA-115 by Novartis for Malignant Mesothelioma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
The company offers generic medicines and biosimilars through Sandoz. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others.
Koye Pharma allies with Sonde on vocal biomarkers for COPD
pharmaphorum
AUGUST 25, 2022
Koye sells generic medicines, including COPD therapies such as Spirodin (doxofylline) and Spirodin-Ax (doxofylline and ambroxol), used to reduce open the airways and reduce coughing in patients with the respiratory condition.
Supply chain middlemen ‘pocket half of US branded medicine spending’
pharmaphorum
JANUARY 13, 2022
Over the same period, total gross expenditures on brand and generic medicines nearly doubled – from $268 billion to $517 billion, according to the report.
Iptacopan hydrochloride by Novartis for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
The company offers generic medicines and biosimilars through Sandoz. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others.
Iptacopan hydrochloride by Novartis for Glomerulonephritis: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
The company offers generic medicines and biosimilars through Sandoz. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others.
CHMP meeting highlights – March 2023
European Pharmaceutical Review
APRIL 3, 2023
The committee adopted positive opinions for three generic medicines: Dabigatran Etexilate Accord (dabigatran etexilate) for the prevention of venous thromboembolic events Lacosamide Adroiq (lacosamide) for epilepsy Sugammadex Adroiq (sugammadex) for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.
Vaccines 83
83 
Amazon unveils $5 subscription service for generics
pharmaphorum
JANUARY 24, 2023
Efforts by Amazon to disrupt the healthcare sector just stepped up a gear, with the launch of a subscription service for Prime members that will ship generic medicines to patients’ homes in return for a $5 monthly fee.
CHMP meeting highlights – January 2023
European Pharmaceutical Review
JANUARY 30, 2023
Four new medicines recommended for approval The CHMP recommended granting a marketing authorisation for Sotyktu (deucravacitinib) for the treatment of moderate to severe plaque psoriasis in adults. Sitagliptin/Metformin hydrochloride Sun (sitagliptin/metformin hydrochloride) for the treatment of type 2 diabetes mellitus.
Small molecule API market to value $284.7 billion by 2032
European Pharmaceutical Review
JULY 25, 2023
The small molecule API market is influenced by several factors, including heightened R&D within the pharmaceutical sector, a growing prevalence of chronic illnesses and rising demand for generic medicines.
Compounding 78
78 
Teva poaches Vertex exec as new head of R&D
pharmaphorum
JULY 4, 2022
. “As such, it is with great responsibility that I will take on the inspiring task to lead the company’s strong and unique R&D organisation, knowing that together with our scientists, researchers and staff we have a tremendous opportunity to bring meaningful specialty, biologics and generics medicines to patients worldwide.”
Sertraline: Everything you need to know about generic Zoloft
The Checkup by Singlecare
JULY 17, 2023
Brand-name and generic Zoloft are available in a few different formulations: tablets, capsules, and oral liquid. Food Drug Administration (FDA) , a generic medicine works in the same way and provides the same clinical benefit as brand-name medicine. The primary difference between generic vs. brand-name drugs is the cost.
Astellas facing generics to big-selling Lexiscan product in US
pharmaphorum
SEPTEMBER 26, 2022
Astellas has won a reprieve in its attempt to stop Pfizer’s generic medicines unit Hospira launching a copycat version of its pharmacologic stress agent Lexiscan in the US – but only for a couple of weeks.
Takeda dengue vaccine receives positive CHMP opinion
pharmaphorum
OCTOBER 17, 2022
The purpose of the EMA’s EU-M4all initiative is to support parallel applications, so as to make innovative or generic medicines and vaccines to address unmet medical needs, or which serve a major public health interest, more quickly, while at the same time avoiding duplication of efforts by regulators.
Vaccines 52
52 
CHMP meeting highlights – December 2022
European Pharmaceutical Review
DECEMBER 19, 2022
A generic medicine, Diethyl fumarate Accord (dimethyl fumarate), received a positive opinion for the treatment of multiple sclerosis (MS), a chronic disease affecting the central nervous system. This rare genetic disorder causes muscle weakness and is often fatal.
STAT+: ‘Like playing the lottery’: A mixed picture for laid-off life sciences workers in Massachusetts
STAT
OCTOBER 10, 2023
The big blow to Sunovion, he said, was the loss of patent protection for Latuda, its best-selling schizophrenia drug, which led to competition from cheaper generic medicines. Janoschek, 56, had worked for Sunovion and a predecessor firm for 22 years and lost his job in March in a restructuring that shed hundreds of workers.
Vaccines 128
128 
Risk adjusted net present value: What is the current valuation of Novartis’s Gevokizumab?
Pharmaceutical Technology
FEBRUARY 18, 2023
The company offers generic medicines and biosimilars through Sandoz. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others.
Let's personalize your content